Compare Atmos Energy Corporation (ATO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.38B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.7× Atmos Energy Corporation's market cap, and Atmos Energy Corporation pays a 2.38% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ATO | VRTX | |
|---|---|---|
Market Cap | $28.38B | $132.79B |
Sector | Utilities | Health |
52-Week High | $192.25 | $529.65 |
52-Week Low | $162.44 | $376.62 |
Enterprise Value | $38.18B | $126.92B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $170.19, down 1.04% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, beating expectations by 5.9%, and maintains strong fundamentals with 28.5% net income margin and $4.70B revenue. Recent board appointments and dividend declarations highlight corporate stability, while analyst consensus targets $190.57 with 45% buy ratings.
ATO presents a mixed outlook with solid earnings growth and dividend stability offset by bearish technical indicators and negative cash flow trends. The stock offers value through consistent profitability and infrastructure investments, though investors face risks from high capital expenditures and debt levels that could pressure future returns.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
